Figure 1

Significance of inhibitory KIR–HLA receptor–ligand mismatch. (A) Cumulative incidence (CI) of disease progression in patients with different numbers of receptor–ligand mismatch pairs (P=0.02). (B) Event-free survival (EFS) of patients with receptor–ligand mismatch and of those with no mismatch (P=0.01). Progression-free survival was identical to EFS because there was no transplant-related mortality.